|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SBSPON |
Gene summary for SBSPON |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SBSPON | Gene ID | 157869 |
| Gene name | somatomedin B and thrombospondin type 1 domain containing | |
| Gene Alias | C8orf84 | |
| Cytomap | 8q21.11 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IVN8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 157869 | SBSPON | P2T-E | Human | Esophagus | ESCC | 2.20e-48 | 1.02e+00 | 0.1177 |
| 157869 | SBSPON | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 2.37e-01 | 0.1131 |
| 157869 | SBSPON | P10T-E | Human | Esophagus | ESCC | 3.66e-63 | 1.34e+00 | 0.116 |
| 157869 | SBSPON | P11T-E | Human | Esophagus | ESCC | 3.25e-05 | 2.98e-01 | 0.1426 |
| 157869 | SBSPON | P12T-E | Human | Esophagus | ESCC | 5.42e-24 | 7.55e-01 | 0.1122 |
| 157869 | SBSPON | P15T-E | Human | Esophagus | ESCC | 1.19e-13 | 5.56e-01 | 0.1149 |
| 157869 | SBSPON | P16T-E | Human | Esophagus | ESCC | 1.12e-95 | 2.53e+00 | 0.1153 |
| 157869 | SBSPON | P19T-E | Human | Esophagus | ESCC | 1.65e-10 | 7.81e-01 | 0.1662 |
| 157869 | SBSPON | P22T-E | Human | Esophagus | ESCC | 1.32e-37 | 1.00e+00 | 0.1236 |
| 157869 | SBSPON | P27T-E | Human | Esophagus | ESCC | 5.06e-41 | 8.87e-01 | 0.1055 |
| 157869 | SBSPON | P28T-E | Human | Esophagus | ESCC | 5.48e-06 | 2.82e-01 | 0.1149 |
| 157869 | SBSPON | P30T-E | Human | Esophagus | ESCC | 1.51e-26 | 1.83e+00 | 0.137 |
| 157869 | SBSPON | P31T-E | Human | Esophagus | ESCC | 1.23e-50 | 1.98e+00 | 0.1251 |
| 157869 | SBSPON | P32T-E | Human | Esophagus | ESCC | 2.61e-14 | 6.02e-01 | 0.1666 |
| 157869 | SBSPON | P49T-E | Human | Esophagus | ESCC | 3.75e-07 | 1.21e+00 | 0.1768 |
| 157869 | SBSPON | P56T-E | Human | Esophagus | ESCC | 5.32e-14 | 2.62e+00 | 0.1613 |
| 157869 | SBSPON | P57T-E | Human | Esophagus | ESCC | 1.72e-04 | 1.83e-01 | 0.0926 |
| 157869 | SBSPON | P62T-E | Human | Esophagus | ESCC | 1.20e-02 | 1.10e-01 | 0.1302 |
| 157869 | SBSPON | P65T-E | Human | Esophagus | ESCC | 4.66e-03 | 1.16e-01 | 0.0978 |
| 157869 | SBSPON | P74T-E | Human | Esophagus | ESCC | 2.13e-33 | 1.37e+00 | 0.1479 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SBSPON | SNV | Missense_Mutation | c.682N>G | p.Gln228Glu | p.Q228E | Q8IVN8 | protein_coding | tolerated(0.06) | benign(0.014) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SBSPON | SNV | Missense_Mutation | novel | c.497C>T | p.Ala166Val | p.A166V | Q8IVN8 | protein_coding | tolerated(0.25) | benign(0.116) | TCGA-E9-A6HE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| SBSPON | insertion | Frame_Shift_Ins | novel | c.356_357insCATTTTGTTTCTTCTTTTTTTTCACACACAAATA | p.Gly120IlefsTer65 | p.G120Ifs*65 | Q8IVN8 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| SBSPON | SNV | Missense_Mutation | c.538N>T | p.His180Tyr | p.H180Y | Q8IVN8 | protein_coding | tolerated(0.39) | benign(0) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| SBSPON | SNV | Missense_Mutation | rs778810907 | c.391N>A | p.Asp131Asn | p.D131N | Q8IVN8 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| SBSPON | SNV | Missense_Mutation | rs766329688 | c.295N>T | p.Arg99Cys | p.R99C | Q8IVN8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SBSPON | SNV | Missense_Mutation | rs765877943 | c.455G>A | p.Arg152Gln | p.R152Q | Q8IVN8 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SBSPON | SNV | Missense_Mutation | rs758346150 | c.296N>A | p.Arg99His | p.R99H | Q8IVN8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-3732-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | capecitabine | SD |
| SBSPON | SNV | Missense_Mutation | rs767468598 | c.782N>C | p.Phe261Ser | p.F261S | Q8IVN8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SBSPON | SNV | Missense_Mutation | rs757345283 | c.284G>A | p.Arg95His | p.R95H | Q8IVN8 | protein_coding | deleterious(0) | possibly_damaging(0.832) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |